Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05494606




Registration number
NCT05494606
Ethics application status
Date submitted
8/08/2022
Date registered
10/08/2022
Date last updated
1/11/2024

Titles & IDs
Public title
An Observational Study to Assess Change in Disease Activity and Adverse Events of Upadacitinib in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Real-World Practice
Scientific title
Prospective Real World Study Of Upadacitinib in Ulcerative Colitis (PROFUNDUS)
Secondary ID [1] 0 0
P22-921
Universal Trial Number (UTN)
Trial acronym
PROFUNDUS
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Ulcerative Colitis 0 0
Condition category
Condition code
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Oral and Gastrointestinal 0 0 0 0
Inflammatory bowel disease

Intervention/exposure
Study type
Observational
Patient registry
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
Participants receiving upadacitinib - Participants receiving upadacitinib for moderate to severe Ulcerative colitis (UC) in real-world practice.
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Median Time to Achieve the First Clinical Response (CR) per Partial Adapted Mayo Score
Timepoint [1] 0 0
Up to approximately week 156
Primary outcome [2] 0 0
Percentage of Participants Achieving Clinical Response (CR) per Partial Adapted Mayo Score Among those who Achieved CR at Completion of Upadacitinib Induction (either at Week 8 or at Week 16)
Timepoint [2] 0 0
Week 52

Eligibility
Key inclusion criteria
* Participants with a diagnosis of moderate to severe Ulcerative colitis (UC).
* Participants initiating upadacitinib at the clinician's discretion as part of their routine clinical care; the decision to administer upadacitinib must be made prior to and independent of recruitment into the study.
* Participants prescribed upadacitinib in accordance with the approved local label.
* Participants able to understand and communicate with the investigator and comply with the requirements of the study.
* Participants willing to continue with study documentation after cessation of upadacitinib.
* Participants willing and able to participate in the collection of patient-reported data via cloud based mobile application using the provided smart device (iPhone).
Minimum age
18 Years
Maximum age
75 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Participants with any contraindication to upadacitinib.
* Participants previously exposed to upadacitinib in a clinical trial.
* Participants currently participating in interventional research (not including noninterventional study, postmarketing observational study (PMOS), or registry participation).

Study design
Purpose
Duration
Selection
Timing
Prospective
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
15/08/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
31/03/2028
Actual
Sample size
Target
1000
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
Blacktown Hospital /ID# 248354 - Blacktown
Recruitment hospital [2] 0 0
Nepean Hospital /ID# 248351 - Kingswood
Recruitment hospital [3] 0 0
Coral Sea Clinical Research institute /ID# 248352 - North Mackay
Recruitment hospital [4] 0 0
Austin Health /ID# 249133 - Heidelberg
Recruitment hospital [5] 0 0
The Royal Melbourne Hospital /ID# 248353 - Parkville
Recruitment postcode(s) [1] 0 0
2148 - Blacktown
Recruitment postcode(s) [2] 0 0
2747 - Kingswood
Recruitment postcode(s) [3] 0 0
4740 - North Mackay
Recruitment postcode(s) [4] 0 0
3084 - Heidelberg
Recruitment postcode(s) [5] 0 0
3050 - Parkville
Recruitment outside Australia
Country [1] 0 0
Argentina
State/province [1] 0 0
Ciudad Autonoma De Buenos Aires
Country [2] 0 0
Argentina
State/province [2] 0 0
Cordoba
Country [3] 0 0
Canada
State/province [3] 0 0
Alberta
Country [4] 0 0
Canada
State/province [4] 0 0
British Columbia
Country [5] 0 0
Canada
State/province [5] 0 0
New Brunswick
Country [6] 0 0
Canada
State/province [6] 0 0
Ontario
Country [7] 0 0
Canada
State/province [7] 0 0
Quebec
Country [8] 0 0
Czechia
State/province [8] 0 0
Jihomoravsky Kraj
Country [9] 0 0
Czechia
State/province [9] 0 0
Praha 9
Country [10] 0 0
Czechia
State/province [10] 0 0
Ceske Budejovice
Country [11] 0 0
Czechia
State/province [11] 0 0
Praha
Country [12] 0 0
France
State/province [12] 0 0
Alpes-Maritimes
Country [13] 0 0
France
State/province [13] 0 0
Bouches-du-Rhone
Country [14] 0 0
France
State/province [14] 0 0
Doubs
Country [15] 0 0
France
State/province [15] 0 0
Gard
Country [16] 0 0
France
State/province [16] 0 0
Haute-Garonne
Country [17] 0 0
France
State/province [17] 0 0
Herault
Country [18] 0 0
France
State/province [18] 0 0
Ile-de-France
Country [19] 0 0
France
State/province [19] 0 0
Isere
Country [20] 0 0
France
State/province [20] 0 0
Loire-Atlantique
Country [21] 0 0
France
State/province [21] 0 0
Loire
Country [22] 0 0
France
State/province [22] 0 0
Marne
Country [23] 0 0
France
State/province [23] 0 0
Nord
Country [24] 0 0
France
State/province [24] 0 0
Paris
Country [25] 0 0
France
State/province [25] 0 0
Provence-Alpes-Cote-d Azur
Country [26] 0 0
France
State/province [26] 0 0
Pyrenees-Atlantiques
Country [27] 0 0
France
State/province [27] 0 0
Rhone
Country [28] 0 0
France
State/province [28] 0 0
Somme
Country [29] 0 0
France
State/province [29] 0 0
Bethune CEDEX
Country [30] 0 0
France
State/province [30] 0 0
Cagnes Sur Mer
Country [31] 0 0
France
State/province [31] 0 0
Colmar
Country [32] 0 0
France
State/province [32] 0 0
Epagny Metz Tessy
Country [33] 0 0
France
State/province [33] 0 0
Montfermeil
Country [34] 0 0
France
State/province [34] 0 0
Nantes
Country [35] 0 0
France
State/province [35] 0 0
Orléans
Country [36] 0 0
France
State/province [36] 0 0
Rennes
Country [37] 0 0
France
State/province [37] 0 0
Strasbourg
Country [38] 0 0
France
State/province [38] 0 0
Toulouse CEDEX 3
Country [39] 0 0
France
State/province [39] 0 0
Vantoux
Country [40] 0 0
Germany
State/province [40] 0 0
Bayern
Country [41] 0 0
Germany
State/province [41] 0 0
Hessen
Country [42] 0 0
Germany
State/province [42] 0 0
Nordrhein-Westfalen
Country [43] 0 0
Germany
State/province [43] 0 0
Rheinland-Pfalz
Country [44] 0 0
Germany
State/province [44] 0 0
Saarland
Country [45] 0 0
Germany
State/province [45] 0 0
Sachsen-Anhalt
Country [46] 0 0
Germany
State/province [46] 0 0
Sachsen
Country [47] 0 0
Germany
State/province [47] 0 0
Schleswig-Holstein
Country [48] 0 0
Germany
State/province [48] 0 0
Alzey
Country [49] 0 0
Germany
State/province [49] 0 0
Andernach
Country [50] 0 0
Germany
State/province [50] 0 0
Berlin-Zehlendorf
Country [51] 0 0
Germany
State/province [51] 0 0
Berlin
Country [52] 0 0
Germany
State/province [52] 0 0
Eschweiler
Country [53] 0 0
Germany
State/province [53] 0 0
Freiburg im Breisgau
Country [54] 0 0
Germany
State/province [54] 0 0
Halle (Saale)
Country [55] 0 0
Germany
State/province [55] 0 0
Hamburg
Country [56] 0 0
Germany
State/province [56] 0 0
Hannover
Country [57] 0 0
Germany
State/province [57] 0 0
Herne
Country [58] 0 0
Germany
State/province [58] 0 0
Leipzig
Country [59] 0 0
Germany
State/province [59] 0 0
Muenster
Country [60] 0 0
Germany
State/province [60] 0 0
Münster
Country [61] 0 0
Germany
State/province [61] 0 0
Nienburg (Weser)
Country [62] 0 0
Germany
State/province [62] 0 0
Nuernberg
Country [63] 0 0
Germany
State/province [63] 0 0
Remscheid
Country [64] 0 0
Germany
State/province [64] 0 0
Tostedt
Country [65] 0 0
Greece
State/province [65] 0 0
Attiki
Country [66] 0 0
Greece
State/province [66] 0 0
Kriti
Country [67] 0 0
Greece
State/province [67] 0 0
Athens
Country [68] 0 0
Greece
State/province [68] 0 0
Thessaloniki
Country [69] 0 0
Ireland
State/province [69] 0 0
Dublin
Country [70] 0 0
Ireland
State/province [70] 0 0
Galway
Country [71] 0 0
Israel
State/province [71] 0 0
H_efa
Country [72] 0 0
Israel
State/province [72] 0 0
HaDarom
Country [73] 0 0
Israel
State/province [73] 0 0
HaMerkaz
Country [74] 0 0
Israel
State/province [74] 0 0
Tel-Aviv
Country [75] 0 0
Israel
State/province [75] 0 0
Haifa
Country [76] 0 0
Italy
State/province [76] 0 0
Bari
Country [77] 0 0
Italy
State/province [77] 0 0
Lombardia
Country [78] 0 0
Italy
State/province [78] 0 0
Milano
Country [79] 0 0
Italy
State/province [79] 0 0
Napoli
Country [80] 0 0
Italy
State/province [80] 0 0
Roma
Country [81] 0 0
Italy
State/province [81] 0 0
Verona
Country [82] 0 0
Italy
State/province [82] 0 0
Palermo
Country [83] 0 0
Italy
State/province [83] 0 0
Pisa
Country [84] 0 0
Kuwait
State/province [84] 0 0
Hawalli
Country [85] 0 0
Portugal
State/province [85] 0 0
Setubal
Country [86] 0 0
Portugal
State/province [86] 0 0
Faro
Country [87] 0 0
Portugal
State/province [87] 0 0
Lisboa
Country [88] 0 0
Portugal
State/province [88] 0 0
Porto
Country [89] 0 0
Portugal
State/province [89] 0 0
Viseu
Country [90] 0 0
Qatar
State/province [90] 0 0
Zone 51
Country [91] 0 0
Russian Federation
State/province [91] 0 0
Voronezh
Country [92] 0 0
Spain
State/province [92] 0 0
Asturias
Country [93] 0 0
Spain
State/province [93] 0 0
Barcelona
Country [94] 0 0
Spain
State/province [94] 0 0
Las Palmas
Country [95] 0 0
Spain
State/province [95] 0 0
Santa Cruz De Tenerife
Country [96] 0 0
Spain
State/province [96] 0 0
Sevilla
Country [97] 0 0
Spain
State/province [97] 0 0
Vizcaya
Country [98] 0 0
Spain
State/province [98] 0 0
Almería
Country [99] 0 0
Spain
State/province [99] 0 0
Huelva
Country [100] 0 0
Spain
State/province [100] 0 0
Salamanca
Country [101] 0 0
United Arab Emirates
State/province [101] 0 0
Abu Dhabi
Country [102] 0 0
United Kingdom
State/province [102] 0 0
Devon
Country [103] 0 0
United Kingdom
State/province [103] 0 0
East Riding Of Yorkshire
Country [104] 0 0
United Kingdom
State/province [104] 0 0
Essex
Country [105] 0 0
United Kingdom
State/province [105] 0 0
Lancashire
Country [106] 0 0
United Kingdom
State/province [106] 0 0
Northamptonshire
Country [107] 0 0
United Kingdom
State/province [107] 0 0
Nottinghamshire
Country [108] 0 0
United Kingdom
State/province [108] 0 0
Oxfordshire
Country [109] 0 0
United Kingdom
State/province [109] 0 0
Belfast
Country [110] 0 0
United Kingdom
State/province [110] 0 0
Liverpool
Country [111] 0 0
United Kingdom
State/province [111] 0 0
London
Country [112] 0 0
United Kingdom
State/province [112] 0 0
Tooting
Country [113] 0 0
United Kingdom
State/province [113] 0 0
Wolverhampton

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
AbbVie
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Ulcerative colitis (UC) is an idiopathic, chronic, inflammatory disease affecting the colon. Participants with UC have mucosal inflammation starting in the rectum that can extend continuously to proximal segments of the colon. This study will assess how safe and effective upadacitinib is in treating adult participants with moderate to severe ulcerative colitis (UC). Adverse events and change in disease activity will be assessed.

Upadacitinib is a drug approved for the treatment of Ulcerative colitis (UC). All study participants will receive upadacitinib as prescribed by their study doctor in accordance with approved local label. Approximately 1000 adult participants will be enrolled worldwide.

Participants will receive upadacitinib as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for up to 3 years.

There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
Trial website
https://clinicaltrials.gov/study/NCT05494606
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
ABBVIE INC.
Address 0 0
AbbVie
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
ABBVIE CALL CENTER
Address 0 0
Country 0 0
Phone 0 0
844-663-3742
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05494606